<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Laboratory assessment of thyroid function</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Laboratory assessment of thyroid function</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Laboratory assessment of thyroid function</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Douglas S Ross, MD</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">David S Cooper, MD</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean E Mulder, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Dec 06, 2023.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Secretion of the thyroid hormones T4 (thyroxine) and T3 (triiodothyronine) is regulated by pituitary thyroid-stimulating hormone (TSH)  (<a class="graphic graphic_figure graphicRef75399" href="/d/graphic/75399.html" rel="external">figure 1</a> and <a class="graphic graphic_figure graphicRef76931" href="/d/graphic/76931.html" rel="external">figure 2</a>). TSH secretion, in turn, is controlled through negative feedback by thyroid hormones (see  <a class="medical medical_review" href="/d/html/7837.html" rel="external">"Thyroid hormone synthesis and physiology"</a>). There is a negative log-linear relationship between serum free T4 and TSH concentrations [<a href="#rid1">1</a>]. This means that very small changes in serum free T4 concentrations induce very large reciprocal changes in serum TSH concentrations. As a result, thyroid function is best assessed by measuring serum TSH, assuming steady-state conditions and the absence of pituitary or hypothalamic disease. Nevertheless, direct measurement of serum thyroid hormone levels is still important since it may be difficult in some patients to be certain about the state of pituitary and hypothalamic function.</p><p>This topic review will provide an overview of thyroid function testing. More detailed discussions of serum TSH and free thyroid hormone measurements, abnormalities in thyroid hormone binding proteins, and the effects of drugs and nonthyroidal illness on thyroid function tests are discussed separately. (See  <a class="medical medical_review" href="/d/html/7845.html" rel="external">"Drug interactions with thyroid hormones"</a> and  <a class="medical medical_review" href="/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a> and  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults"</a> and  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism"</a>.)</p><p class="headingAnchor" id="H2"><span class="h1">LABORATORY TESTS USED TO ASSESS THYROID FUNCTION</span><span class="headingEndMark"> — </span>Thyroid function is assessed by one or more of the following tests:</p><p class="bulletIndent1"><span class="glyph">●</span>Serum TSH concentration</p><p class="bulletIndent1"><span class="glyph">●</span>Serum total T4 and T3 concentrations</p><p class="bulletIndent1"><span class="glyph">●</span>Serum free T4 and T3 concentrations</p><p></p><p>There are multiple methods for measuring TSH, total T4 and total T3, and free T4 and free T3 [<a href="#rid2">2</a>]. In most hospital or clinical laboratories in the United States, a "full" set of thyroid function tests usually includes an automated immunometric chemiluminescent third-generation TSH level, an automated "direct" competitive-binding chemiluminescent free T4, and a total T3 or free T3 assay [<a href="#rid2">2</a>]. Most clinical laboratories also offer a total T4 assay. Other assays are costly and require referral to a reference laboratory.</p><p class="headingAnchor" id="H2425832550"><span class="h2">Assay interference with biotin ingestion</span><span class="headingEndMark"> — </span>Patients taking <a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> should hold the supplement for two days prior to assessing thyroid function and longer if they are taking more than 10 mg a day.</p><p>Some automated assays for measurement of thyroid tests utilize a biotin-streptavidin separation system [<a href="#rid3">3</a>]. Patients who are ingesting 5 to 10 mg of <a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> (eg, marketed over the counter to prevent hair loss) can have spurious results in these assays. Biotin may cause falsely low values in immunometric assays (eg, used to measure TSH), and falsely high values in competitive binding assays (eg, used to measure free T4, T3, and free T3, and TSH receptor-binding inhibitor immunoglobulin [TBII or TBI]) [<a href="#rid4">4,5</a>]. (See  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/7881.html" rel="external">"Subclinical hyperthyroidism in nonpregnant adults", section on 'Differential diagnosis'</a>.)</p><p class="headingAnchor" id="H3"><span class="h2">Serum TSH</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assays</strong> – Third-generation TSH chemiluminometric assays, currently in wide use, have detection limits of approximately 0.01 mU/L. They can therefore provide detectable TSH measurements even in mild hyperthyroidism [<a href="#rid6">6</a>]. Because of the considerably lower detection limit, even with poor quality control, serum TSH values in patients with overt hyperthyroidism are easily distinguished from those in euthyroid patients [<a href="#rid7">7</a>].</p><p></p><p class="bulletIndent1">Second-generation TSH immunometric assays have detection limits of approximately 0.1 mU/L, and they are still used in some laboratories as screening tests to distinguish hyperthyroidism from euthyroidism and to assess the degree of hypothyroidism [<a href="#rid8">8</a>]. However, values near or at the detection limit do not distinguish the degree of hyperthyroidism, and poor quality control in many laboratories can lead to erroneous values [<a href="#rid9">9</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reference range</strong> – There is considerable controversy as to the appropriate upper limit of normal for serum TSH. Most laboratories have used values of approximately 4.5 to 5.0 mU/L. Although age-adjusted reference ranges for TSH are not routinely reported by clinical laboratories, we and others favor using aged-based normal ranges for TSH [<a href="#rid10">10</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Age-related increase in TSH</strong> – The distribution of TSH values in the population differs by age. In an analysis of 16,533 individuals in the National Health and Nutrition Examination Survey III (NHANES III), there was an age-related shift toward higher TSH concentrations in older patients, which persisted when those with positive antithyroid antibodies were excluded [<a href="#rid11">11</a>]. For example, the 97.5 centile for TSH in adults aged 20 to 29 years, or over age 80, was 3.56 and 7.49 mU/L, respectively. Seventy percent of the individuals in the older group with a TSH greater than 4.5 mU/L were within the normal range for their age. Similar age-associated increases in serum TSH concentrations were found in other prospective cohort studies [<a href="#rid10">10,12-14</a>]. </p><p></p><p class="bulletIndent2">Controversy exists as to whether patients with serum TSH values between 5 and 10 mU/L with normal free T4 levels (subclinical hypothyroidism) require treatment. If age-adjusted normal ranges for TSH were employed, 60 percent of women diagnosed with subclinical hypothyroidism would be considered euthyroid [<a href="#rid15">15</a>]. (See  <a class="medical medical_review" href="/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults"</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Optimal TSH and cardiovascular and skeletal outcomes</strong> – Higher TSH levels within the normal reference range may be associated with health (eg, cardiovascular, skeletal) benefits rather than health problems in older adults [<a href="#rid16">16,17</a>]. As an example, in a systematic review and meta-analysis of individual patient data, TSH levels between the 60<sup>th</sup> and the 80<sup>th</sup> percentile of the normal reference range (median 1.9 to 2.9 mU/L) were associated with the lowest risk of cardiovascular disease and mortality [<a href="#rid16">16</a>]. These data suggest that the determination of optimal TSH levels should include an assessment of cardiovascular and skeletal outcomes.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Other factors that may impact TSH reference range</strong> – A weight-related shift upward in the reference range for TSH among people with class II or class III obesity has been reported [<a href="#rid18">18</a>]. The NHANES III study found that persons of African descent have a TSH distribution that is shifted downward, so that 3 to 4 percent of healthy Black individuals have a serum TSH &lt;0.4 mU/L [<a href="#rid19">19</a>].</p><p></p><p class="bulletIndent1">A monograph published by the National Academy of Clinical Biochemistry argued that the upper limit of normal of the euthyroid reference range should be reduced to 2.5 mU/L because 95 percent of rigorously screened euthyroid volunteers have serum values between 0.4 and 2.5 mU/L [<a href="#rid20">20</a>]. However, a population study from Germany, which excluded patients with a positive family history, goiter, nodules, or positive antithyroid peroxidase (TPO) antibodies, found a normal reference range of 0.3 to 3.63 mU/L [<a href="#rid21">21</a>]. The use of 2.5 or 3.63 mU/L as the upper limit of normal for serum TSH will increase substantially the number of patients in the United States diagnosed with subclinical hypothyroidism, and treatment may result in adverse outcomes, especially in the older adult population. Until there are data demonstrating an adverse biologic significance for age-adjusted serum TSH values between 2.5 to 3.5 mU/L and the age-adjusted upper limit of normal, the wisdom of labeling such patients as hypothyroid is questionable.</p><p></p><p class="headingAnchor" id="H4"><span class="h2">Serum total T4 and T3</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assays</strong> – Serum total T4 is usually measured by automated competitive binding chemiluminometric assays. Older competitive binding radioimmunoassays are still available. Virtually all (99.97 percent) of serum T4 is bound to TBG (thyroxine-binding globulin), transthyretin (also called TBPA [thyroxine-binding prealbumin]), and albumin. Serum total T4 assays measure both bound and unbound ("free") T4.</p><p></p><p class="bulletIndent1">Serum total T3 is also usually measured by automated competitive binding chemiluminescent assays. T3 is less tightly bound to TBG and TBPA but more tightly bound to albumin than T4.</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Reference range</strong> – Normal ranges vary among laboratories; a typical reference range for total T4 is 4.6 to 11.2 mcg/dL (60 to 145 nmol/L). The normal range for total T3 is even more variable among laboratories than that for total T4; a typical range is approximately 75 to 195 ng/dL (1.1 to 3 nmol/L).</p><p></p><p class="headingAnchor" id="H5"><span class="h2">Serum free T4 and T3</span><span class="headingEndMark"> — </span>The free hormone hypothesis states that the unbound or free hormone is the fraction that is available for uptake into cells and interaction with nuclear receptors [<a href="#rid22">22</a>]. The bound hormone, on the other hand, represents a circulating storage pool that is not immediately available for uptake into cells.</p><p>Since drugs and illness can alter concentrations of binding proteins or interaction of the binding proteins with T4 or T3  (<a class="graphic graphic_table graphicRef50439" data-inline-graphics="50439" href="/d/graphic/50439.html" rel="external">table 1</a>), the free and total hormone concentrations may not be concordant. An example is estrogen-induced TBG excess, in which total T4 concentrations are high due to increased TBG-bound hormone, but the physiologically important free T4 concentrations are normal (see  <a class="medical medical_review" href="/d/html/7892.html" rel="external">"Euthyroid hyperthyroxinemia and hypothyroxinemia"</a>). It is therefore necessary to estimate free hormone concentrations.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assays</strong> – Most laboratories measure free T4 and free T3 by "direct" measurement.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>"Direct" free T4</strong> – Direct free T4 measurements can be automated, and varying methodologies have been used by commercial laboratories [<a href="#rid23">23</a>]; however, none of these actually measure unbound T4 directly since free hormone represents only 0.03 percent of serum total T4. The perceived advantage of direct free T4 measurement is that confusion related to binding protein abnormalities is mitigated by providing values that allegedly take binding abnormalities into account. The disadvantage is that no currently available assay provides correct free T4 values for all the binding abnormalities that have been described. Direct free T4 measurements may be unreliable during pregnancy due to low albumin and other factors (see  <a class="medical medical_review" href="/d/html/7851.html" rel="external">"Overview of thyroid disease and pregnancy"</a>) and in malnourished or critically ill patients due to low levels of binding proteins (see  <a class="medical medical_review" href="/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a>). The normal range also varies with the methodology used.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>"Direct" free T3</strong> – Direct free T3 measurements use similar methodology and are increasingly available, but these assays demonstrate even higher variability than the free T4 assays, and we agree with American Thyroid Association guidelines that the use of total T3 measurements are more reliable [<a href="#rid2">2,24</a>].</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Free T4 index, calculated using the T3 uptake (or THBI)</strong> – This older method for estimating the free T4 concentration is still in use. Calculation of the free T4 index has the advantage that the clinician is given both a total T4 and a T3 uptake or thyroid hormone binding index (THBI), making it clear when the patient has a potential binding protein abnormality. The disadvantages are: (1) the calculation is poorly understood by many clinicians, and (2) the free T4 index, as with direct free T4 measurements, fails to give correct values for many described binding protein abnormalities. (See  <a class="medical medical_review" href="/d/html/7892.html" rel="external">"Euthyroid hyperthyroxinemia and hypothyroxinemia"</a>.)</p><p></p><p class="bulletIndent2">The traditional T3-uptake test is performed by incubating the patient's serum with radiolabeled T3 tracer and subsequently adding an insoluble substance (dextran-coated charcoal or "resin") that traps the remaining unbound radiolabeled T3. The value reported is the percent of tracer bound to the resin, which varies inversely with the number of available free binding sites for T3. The number of free binding sites is determined by both binding protein levels and endogenous hormone production.</p><p></p><p class="bulletIndent2">The normal range varies considerably among laboratories. While many laboratories still report the actual measured value for the T3 uptake, it is preferable to calculate a THBI, which is simply a normalized T3-resin uptake value [<a href="#rid25">25</a>]:</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2">THBI  =  patient's T3 uptake  ÷  normal pool T3 uptake</p></div></div><p></p><p class="bulletIndent2">The mean THBI is, therefore, by definition 1.00, with a normal range of approximately 0.83 to 1.16. Some laboratories call the THBI the thyroid hormone-binding ratio (THBR).</p><p></p><p class="bulletIndent2">The free T4 index is calculated by "correcting" the total T4 by the T3 uptake or THBI:</p><p></p><div class="formulaContainer"><div class="formula"><p class="bulletIndent2">Free T4 index  =  total T4  x  T3 uptake,  or free T4 index  =  total T4  x  THBI</p></div></div><p></p><p class="bulletIndent2">If the index is calculated by using the T3-uptake, the result is a unitless number with a normal range distinct for the laboratory. If the index is calculated using the THBI, the index should have approximately the same normal range as the total T4 values for the laboratory.</p><p></p><p class="bulletIndent2">The T3-uptake was designed to distinguish TBG excess and deficiency from hyperthyroidism and hypothyroidism:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Hyperthyroidism – High serum total T4, high T3-uptake or THBI, high free T4 index</p><p class="bulletIndent3"><span class="glyph">-</span>TBG excess – High serum total T4, low T3-uptake or THBI, normal free T4 index</p><p class="bulletIndent3"><span class="glyph">-</span>Hypothyroidism – Low serum total T4, low T3-uptake or THBI, low free T4 index</p><p class="bulletIndent3"><span class="glyph">-</span>TBG deficiency – Low serum total T4, high T3-uptake or THBI, normal free T4 index</p><p></p><p class="bulletIndent2">However, the index may not fully correct at the extremes of binding protein abnormalities.</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Equilibrium dialysis</strong> – Measurement of free T4 by equilibrium dialysis is available only in a few reference laboratories. The classic technique measures the distribution of free T4 at equilibrium across a dialysis membrane to estimate the unbound fraction. The method is too tedious and expensive for routine use. (See  <a class="medical medical_review" href="/d/html/7845.html" rel="external">"Drug interactions with thyroid hormones", section on 'Drugs that affect thyroid hormone metabolism or clearance'</a>.)</p><p></p><p class="headingAnchor" id="H561296658"><span class="h2">Reverse T3</span><span class="headingEndMark"> — </span>Reverse T3 (rT3) is an inactive metabolite of thyroxine. It is widely measured by alternative health practitioners to justify the use of T3 therapy and supplements thought to enhance the conversion of T4 to T3. It has extremely limited utility for conventional medical practitioners for assessing rare conditions such as consumptive hypothyroidism, <em>MCT8</em> or <em>SBP2</em> mutations, or possibly distinguishing central hypothyroidism from nonthyroidal illness in critically ill hospitalized patients [<a href="#rid2">2,26</a>].</p><p class="headingAnchor" id="H7"><span class="h1">CLINICAL USE OF THYROID FUNCTION TESTS</span><span class="headingEndMark"> — </span>Thyroid function tests are used in a variety of clinical settings to evaluate thyroid dysfunction, assess the adequacy of <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> therapy, and monitor the treatment of hyperthyroidism  (<a class="graphic graphic_table graphicRef67935" data-inline-graphics="67935" href="/d/graphic/67935.html" rel="external">table 2</a>). Assuming steady-state conditions and the absence of pituitary or hypothalamic disease, thyroid function is best assessed by measuring serum TSH. However, measurement of serum TSH and thyroid hormone levels remains important in patients with symptoms of possible thyroid dysfunction since a normal serum TSH does not unequivocally exclude the possibility of central hypothyroidism or central hyperthyroidism from a TSH secreting tumor.</p><p>"Screening" refers to the measurement of thyroid function tests in asymptomatic patients at risk of having thyroid disease who are presently not known to have thyroid disease. There is some debate over the cost effectiveness of screening or case finding in apparently asymptomatic patients. This topic is reviewed in detail elsewhere. (See  <a class="medical medical_review" href="/d/html/7893.html" rel="external">"Diagnosis of and screening for hypothyroidism in nonpregnant adults", section on 'Screening'</a>.)</p><p class="headingAnchor" id="H8"><span class="h2">Evaluating for thyroid dysfunction</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Outpatient setting</strong> – When evaluation is performed in the outpatient setting, many laboratories use the following strategies to limit unnecessary laboratory testing:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum TSH normal – No further testing performed</p><p class="bulletIndent2"><span class="glyph">•</span>Serum TSH high – Free T4 added to determine the degree of hypothyroidism</p><p class="bulletIndent2"><span class="glyph">•</span>Serum TSH low – Free T4 and T3 added to determine the degree of hyperthyroidism</p><p></p><p class="bulletIndent1">We make two amendments to this strategy when used to assess possible thyroid dysfunction in an individual patient:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We measure both serum TSH and free T4 if pituitary or hypothalamic disease is suspected (eg, a young woman with amenorrhea and fatigue).</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>We measure serum free T4 if the patient has symptoms of hyper- or hypothyroidism despite a normal TSH result.</p><p></p><p class="bulletIndent1">Serum TSH assays are both more sensitive and specific than serum free T4 measurements for outpatients if a single test is utilized [<a href="#rid2">2,27</a>]. However, some experts recommend that both serum TSH and free T4 be measured in all patients for evaluation purposes since errors may be made when only TSH is measured in patients with secondary or central hypothyroidism or TSH-mediated hyperthyroidism. This approach adds considerable cost to screening and is likely to pick up few cases of unsuspected pituitary disease. As an example, in a study of 4843 community-dwelling individuals, measuring a TSH only would have missed 3.8 percent of patients with an abnormal free T4, and 85 percent of these patients had only minimally high or low free T4 concentrations [<a href="#rid28">28</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Inpatient setting</strong> – Evaluating thyroid function in the inpatient setting is a more difficult problem, and it is not recommended unless thyroid disease is strongly suspected, since changes in thyroid hormones, binding proteins, and TSH concentrations occur in severe nonthyroidal illness (see  <a class="medical medical_review" href="/d/html/7817.html" rel="external">"Thyroid function in nonthyroidal illness"</a>). These changes may include [<a href="#rid29">29</a>]:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Low concentrations of all three binding proteins</p><p class="bulletIndent2"><span class="glyph">•</span>High concentrations of free fatty acids that displace thyroid hormones from binding proteins</p><p class="bulletIndent2"><span class="glyph">•</span>Acquired central hypothyroidism</p><p class="bulletIndent2"><span class="glyph">•</span>The patient may be receiving medications that affect thyroid function  (<a class="graphic graphic_table graphicRef50439" href="/d/graphic/50439.html" rel="external">table 1</a>)</p><p></p><p class="bulletIndent1">While there are advocates for either serum TSH or free T4 being more useful in inpatients, most experts suggest that both serum TSH and free T4 or total T4 are necessary to assess thyroid function in hospitalized patients [<a href="#rid30">30-32</a>].</p><p></p><p class="headingAnchor" id="H9"><span class="h2">Monitoring levothyroxine therapy</span><span class="headingEndMark"> — </span>One of the more common reasons for assessing thyroid function is to assess the adequacy of <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> therapy.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Primary hypothyroidism</strong> – Patients with primary hypothyroidism who are taking <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> replacement therapy can be monitored by assessing the serum TSH only. In general, serum free T4 measurements are very insensitive for assessing the appropriateness of the levothyroxine dose. Doses of levothyroxine that are 40 percent higher than optimal may result in subnormal serum TSH concentrations, yet serum free T4 concentrations frequently remain within the normal range [<a href="#rid33">33</a>]. Conversely, some patients who take levothyroxine may have high free T4 and normal TSH levels, depending on the timing of blood testing and levothyroxine ingestion [<a href="#rid34">34</a>]. Nevertheless, free T4 measurements can be useful to determine appropriate dose increases or decreases when TSH is very high or low, respectively. (See  <a class="medical medical_review" href="/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Initial monitoring and dose adjustments'</a> and  <a class="medical medical_review" href="/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Adjustment of maintenance dose'</a>.)</p><p></p><p class="bulletIndent1"><a class="drug drug_general" data-topicid="9563" href="/d/drug information/9563.html" rel="external">Liothyronine</a> (T3, Cytomel) is generally not recommended for treating hypothyroidism. However, in patients with persistent hypothyroid symptoms on <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> monotherapy, T3 is sometimes added. In this setting, we do not routinely monitor T3 levels. With the currently available T3-containing preparations, there are wide fluctuations in T3 concentrations throughout the day due to its rapid gastrointestinal absorption and its relatively short half-life in the circulation (approximately one day), thus T3 measurement primarily reflects the elapsed time since ingestion of T3. (See  <a class="medical medical_review" href="/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Monitoring combined therapy'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Secondary hypothyroidism</strong> – The one setting in which the serum free T4 value should be used to titrate the thyroid hormone dose is in patients with secondary hypothyroidism due to pituitary or hypothalamic disease who have absent or impaired TSH release. In this situation, the free T4 level should be maintained in the upper 50 percent of the normal range. (See  <a class="medical medical_review" href="/d/html/7849.html" rel="external">"Central hypothyroidism", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid cancer</strong> – The goal and requirement for monitoring are different in patients taking <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> for suppression of TSH secretion to prevent recurrence of thyroid cancer. (See  <a class="medical medical_review" href="/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Thyroid hormone suppression'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid nodules and goiter</strong> – Rarely, mild suppression of TSH with <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> is used to prevent growth or regrowth of goitrous tissue. (See  <a class="medical medical_review" href="/d/html/7887.html" rel="external">"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter"</a>.)</p><p></p><p class="headingAnchor" id="H10"><span class="h2">Monitoring treatment of hyperthyroidism</span><span class="headingEndMark"> — </span>During the early treatment of hyperthyroidism with antithyroid drugs, radioiodine, or surgery, serum TSH may remain subnormal for several weeks and rarely for several months. Initial monitoring of therapy, therefore, should consist of periodic clinical assessment, measurements of serum free T4, and often measurements of total T3 levels. Serum T3 concentrations may be disproportionately higher than serum T4 concentrations in many types of hyperthyroidism. Also, serum free T4 levels may normalize with antithyroid drug therapy, while serum T3 levels may remain persistently elevated. Once steady-state conditions are assured, measurement of serum TSH only can be used to assess the efficacy of therapy. (See  <a class="medical medical_review" href="/d/html/7872.html" rel="external">"Graves' hyperthyroidism in nonpregnant adults: Overview of treatment", section on 'Monitoring after treatment'</a>.)</p><p class="headingAnchor" id="H11"><span class="h1">ANTITHYROID ANTIBODIES</span><span class="headingEndMark"> — </span>Several antibodies against thyroid antigens have been described in chronic autoimmune thyroiditis and Graves' disease. However, routine measurement of antithyroid antibodies is not necessary for the assessment of thyroid function.</p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroglobulin</strong> (Tg, formerly known as the colloid antigen) – Tg is synthesized by follicular cells and secreted into the lumen of the thyroid follicle, where it is stored as colloid. Patients with Hashimoto's thyroiditis or Graves' disease may have thyroglobulin antibodies, but thyroglobulin antibodies do not need to be measured to diagnose autoimmune thyroid disease. However, thyroglobulin antibodies can interfere with the measurement of serum thyroglobulin, and they are therefore always assessed when monitoring serum thyroglobulin levels in patients with differentiated thyroid cancer. (Thyroglobulin is used for the detection of residual, recurrent, or metastatic disease.) (See  <a class="medical medical_review" href="/d/html/2193.html" rel="external">"Differentiated thyroid cancer: Role of serum thyroglobulin", section on 'Thyroglobulin antibodies'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Thyroid peroxidase</strong> (TPO, formerly known as the microsomal antigen) – TPO catalyzes the iodination of tyrosine residues of Tg to form monoiodotyrosine and diiodotyrosine. Nearly all patients with Hashimoto's thyroiditis have high serum concentrations of TPO antibodies. Serum anti-TPO antibodies need not be measured in patients with overt primary hypothyroidism, because almost all have chronic autoimmune thyroiditis. However, a test for anti-TPO antibodies may be useful to predict the likelihood of progression to permanent overt hypothyroidism in patients with subclinical hypothyroidism. (See  <a class="medical medical_review" href="/d/html/7883.html" rel="external">"Subclinical hypothyroidism in nonpregnant adults", section on 'Identifying the cause'</a>.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>The TSH receptor</strong> – Thyrotropin receptor antibodies (TRAbs) are classified as stimulating, blocking, or neutral. Stimulating antibodies (thyroid-stimulating immunoglobulins, TSI) cause Graves' disease. Thyroid receptor-blocking antibodies can cause hypothyroidism. Some patients will have a mixture of both antibodies, and, depending on the relative titers of these antibodies, they may fluctuate between hyperthyroidism and hypothyroidism. Neutral antibodies bind the receptor but do not stimulate or block function.</p><p></p><p class="bulletIndent1">There are two methods for measuring TRAb:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>TSI assays measure only thyroid-stimulating antibodies</p><p class="bulletIndent2"><span class="glyph">•</span>TSH receptor-binding inhibitor immunoglobulin (TBII or TBI) assays measure stimulating, blocking, and neutral antibodies.</p><p></p><p class="bulletIndent1">Third-generation TSI assays have been reported to have a sensitivity of 97 percent and a specificity of 99 percent for the diagnosis of Graves' disease [<a href="#rid35">35</a>]. However, sensitivity may be lower in patients with mild hyperthyroidism [<a href="#rid36">36</a>]. Some third-generation TBII assays are automated and less expensive but are not specific for stimulating antibodies.</p><p></p><p class="bulletIndent1">Measurement of TRAb is unnecessary for establishing the cause of hyperthyroidism if a radioiodine uptake has been obtained. However, TRAb measurements are being used increasingly as an alternative to obtaining a radioiodine uptake when Graves' disease is suspected. TRAb measurements are also useful for assessing the likelihood of remission after a 12- to 18-month course of antithyroid drugs in patients with Graves' disease, and many experts will obtain a baseline measurement early in the course of antithyroid drug treatment. (See  <a class="medical medical_review" href="/d/html/7847.html" rel="external">"Diagnosis of hyperthyroidism", section on 'Determining the etiology'</a> and  <a class="medical medical_review" href="/d/html/7831.html" rel="external">"Postpartum thyroiditis", section on 'Differential diagnosis'</a> and  <a class="medical medical_review" href="/d/html/7876.html" rel="external">"Thionamides in the treatment of Graves' disease", section on 'Evaluation prior to stopping therapy'</a>.)</p><p></p><p class="bulletIndent1">There are no commercial assays for blocking antibodies available in the United States, but one such assay is available in Europe. When considering the presence of blocking antibodies in patients with fluctuating hyper- and hypothyroidism (or initial hyperthyroidism, followed by hypothyroidism), a negative TSI level and a positive TBII level, or a TBII level that is considerably higher than the TSI level, is indirect evidence for the possible presence of blocking antibodies.</p><p></p><p class="headingAnchor" id="H12"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)</p><p class="bulletIndent1"><span class="glyph">●</span>Basics topics (see  <a class="medical medical_basics" href="/d/html/15438.html" rel="external">"Patient education: Hypothyroidism (underactive thyroid) (The Basics)"</a> and  <a class="medical medical_basics" href="/d/html/15437.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (The Basics)"</a>)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Beyond the Basics topics (see  <a class="medical medical_patient" href="/d/html/2179.html" rel="external">"Patient education: Hypothyroidism (underactive thyroid) (Beyond the Basics)"</a> and  <a class="medical medical_patient" href="/d/html/2178.html" rel="external">"Patient education: Hyperthyroidism (overactive thyroid) (Beyond the Basics)"</a>)</p><p></p><p class="headingAnchor" id="H30113367"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Laboratory tests to assess thyroid function</strong> – Thyroid function is assessed by one or more of the following tests:</p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Serum thyroid-stimulating hormone (TSH) concentration</p><p class="bulletIndent2"><span class="glyph">•</span>Serum total thyroxine (T4) and triiodothyronine (T3) concentrations</p><p class="bulletIndent2"><span class="glyph">•</span>Serum free T4 and T3 concentrations</p><p></p><p class="bulletIndent1">Very small changes in serum free T4 concentrations induce very large reciprocal changes in serum TSH concentrations  (<a class="graphic graphic_figure graphicRef75399" href="/d/graphic/75399.html" rel="external">figure 1</a>). As a result, thyroid function is best assessed by measuring serum TSH, assuming steady-state conditions and the absence of pituitary or hypothalamic disease. However, direct measurement of serum thyroid hormone levels remains important in many patients since it may be difficult in some patients to be certain about the state of pituitary and hypothalamic function. (See <a class="local">'Laboratory tests used to assess thyroid function'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Assay interference with </strong><a class="drug drug_general" data-topicid="120386" href="/d/drug information/120386.html" rel="external">biotin</a> – Patients taking biotin should hold the supplement for two days prior to assessing thyroid function and longer if they are taking more than 10 mg a day. (See <a class="local">'Assay interference with biotin ingestion'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Clinical use of thyroid tests</strong> – Thyroid function tests are used in a variety of clinical settings to evaluate thyroid dysfunction, assess the adequacy of <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> therapy in patients with hypothyroidism, and monitor the treatment of hyperthyroidism  (<a class="graphic graphic_table graphicRef67935" href="/d/graphic/67935.html" rel="external">table 2</a>). (See <a class="local">'Clinical use of thyroid function tests'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Evaluation of thyroid dysfunction</strong> – When evaluation is performed in the outpatient setting, many laboratories use the following strategies to limit unnecessary laboratory testing:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>Serum TSH normal – No further testing performed</p><p class="bulletIndent3"><span class="glyph">-</span>Serum TSH high – Free T4 added to determine the degree of hypothyroidism</p><p class="bulletIndent3"><span class="glyph">-</span>Serum TSH low – Free T4 and T3 added to determine the degree of hyperthyroidism</p><p></p><p class="bulletIndent2">We make two amendments to this strategy when used to assess possible thyroid dysfunction in an individual patient:</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We measure both serum TSH and free T4 if pituitary or hypothalamic disease is suspected (eg, a young woman with amenorrhea and fatigue).</p><p></p><p class="bulletIndent3"><span class="glyph">-</span>We measure serum free T4 if the patient has symptoms of hyper- or hypothyroidism despite a normal TSH result. (See <a class="local">'Evaluating for thyroid dysfunction'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring </strong><a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a><strong> treatment</strong> – In patients with primary hypothyroidism who are taking levothyroxine replacement therapy, the serum TSH should be used to titrate the thyroid hormone dose. (See <a class="local">'Monitoring levothyroxine therapy'</a> above and  <a class="medical medical_review" href="/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Initial monitoring and dose adjustments'</a> and  <a class="medical medical_review" href="/d/html/7855.html" rel="external">"Treatment of primary hypothyroidism in adults", section on 'Adjustment of maintenance dose'</a>.)</p><p></p><p class="bulletIndent2">In patients with secondary hypothyroidism due to pituitary or hypothalamic disease (absent or impaired TSH release), the serum free T4 value should be used to titrate the thyroid hormone dose. (See <a class="local">'Monitoring levothyroxine therapy'</a> above and  <a class="medical medical_review" href="/d/html/7849.html" rel="external">"Central hypothyroidism", section on 'Treatment'</a>.)</p><p></p><p class="bulletIndent2">The goal and requirement for monitoring are different in patients taking <a class="drug drug_general" data-topicid="9557" href="/d/drug information/9557.html" rel="external">levothyroxine</a> for suppression of TSH secretion to prevent recurrence of thyroid cancer or growth or regrowth of goitrous tissue. (See  <a class="medical medical_review" href="/d/html/7887.html" rel="external">"Thyroid hormone suppressive therapy for thyroid nodules and benign goiter"</a> and  <a class="medical medical_review" href="/d/html/7838.html" rel="external">"Differentiated thyroid cancer: Overview of management", section on 'Thyroid hormone suppression'</a>.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Monitoring treatment of hyperthyroidism – </strong>Initial monitoring of hyperthyroidism treatment should consist of periodic clinical assessment, measurements of serum free T4, and often measurements of total T3 levels. During the early treatment of hyperthyroidism with antithyroid drugs, radioiodine, or surgery, serum TSH may remain subnormal for several weeks and rarely for several months. Once steady-state conditions are assured, measurement of serum TSH only can be used to assess the efficacy of therapy. (See <a class="local">'Monitoring treatment of hyperthyroidism'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Antithyroid antibodies</strong> – Several antibodies against thyroid antigens have been described in chronic autoimmune thyroiditis. However, routine measurement of antithyroid antibodies is not necessary for the assessment of thyroid function. Measurement of thyrotropin receptor antibodies (TRAbs) can be useful in establishing a diagnosis of Graves' disease and assessing the likelihood of remission after a 12- to 18-month course of antithyroid drug therapy. (See <a class="local">'Antithyroid antibodies'</a> above.)</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Spencer CA, LoPresti JS, Patel A, et al. Applications of a new chemiluminometric thyrotropin assay to subnormal measurement. J Clin Endocrinol Metab 1990; 70:453.</a></li><li><a class="nounderline abstract_t">Van Uytfanghe K, Ehrenkranz J, Halsall D, et al. Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status. Thyroid 2023; 33:1013.</a></li><li><a class="nounderline abstract_t">Barbesino G. Misdiagnosis of Graves' Disease with Apparent Severe Hyperthyroidism in a Patient Taking Biotin Megadoses. Thyroid 2016; 26:860.</a></li><li><a class="nounderline abstract_t">Li D, Radulescu A, Shrestha RT, et al. Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults. JAMA 2017; 318:1150.</a></li><li><a class="nounderline abstract_t">Sharma A, Baumann NA, Shah P. Biotin-Induced Biochemical Graves Disease: A Teachable Moment. JAMA Intern Med 2017; 177:571.</a></li><li><a class="nounderline abstract_t">Ross DS, Ardisson LJ, Meskell MJ. Measurement of thyrotropin in clinical and subclinical hyperthyroidism using a new chemiluminescent assay. J Clin Endocrinol Metab 1989; 69:684.</a></li><li><a class="nounderline abstract_t">Spencer CA, Takeuchi M, Kazarosyan M. Current status and performance goals for serum thyrotropin (TSH) assays. Clin Chem 1996; 42:140.</a></li><li><a class="nounderline abstract_t">Caldwell G, Kellett HA, Gow SM, et al. A new strategy for thyroid function testing. Lancet 1985; 1:1117.</a></li><li><a class="nounderline abstract_t">Nicoloff JT, Spencer CA. Clinical review 12: The use and misuse of the sensitive thyrotropin assays. J Clin Endocrinol Metab 1990; 71:553.</a></li><li><a class="nounderline abstract_t">Cappola AR. The Thyrotropin Reference Range Should Be Changed in Older Patients. JAMA 2019; 322:1961.</a></li><li><a class="nounderline abstract_t">Surks MI, Hollowell JG. Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism. J Clin Endocrinol Metab 2007; 92:4575.</a></li><li><a class="nounderline abstract_t">Bremner AP, Feddema P, Leedman PJ, et al. Age-related changes in thyroid function: a longitudinal study of a community-based cohort. J Clin Endocrinol Metab 2012; 97:1554.</a></li><li><a class="nounderline abstract_t">Waring AC, Arnold AM, Newman AB, et al. Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study. J Clin Endocrinol Metab 2012; 97:3944.</a></li><li><a class="nounderline abstract_t">Vadiveloo T, Donnan PT, Murphy MJ, Leese GP. Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the Thyroid Epidemiology, Audit, and Research Study (TEARS). J Clin Endocrinol Metab 2013; 98:1147.</a></li><li><a class="nounderline abstract_t">Yamada S, Horiguchi K, Akuzawa M, et al. The Impact of Age- and Sex-Specific Reference Ranges for Serum Thyrotropin and Free Thyroxine on the Diagnosis of Subclinical Thyroid Dysfunction: A Multicenter Study from Japan. Thyroid 2023; 33:428.</a></li><li><a class="nounderline abstract_t">Xu Y, Derakhshan A, Hysaj O, et al. The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis. Lancet Diabetes Endocrinol 2023; 11:743.</a></li><li><a class="nounderline abstract_t">Zhu X, Li M, Dong X, et al. A systematic review of the relationship between normal range of serum thyroid-stimulating hormone and bone mineral density in the postmenopausal women. BMC Womens Health 2023; 23:358.</a></li><li><a class="nounderline abstract_t">Valdés S, Maldonado-Araque C, Lago-Sampedro A, et al. Reference values for TSH may be inadequate to define hypothyroidism in persons with morbid obesity: <span class="__cf_email__" data-cfemail="bafed3fad8dfce94dfc9">[email protected]</span> study. Obesity (Silver Spring) 2017; 25:788.</a></li><li><a class="nounderline abstract_t">Boucai L, Surks MI. Reference limits of serum TSH and free T4 are significantly influenced by race and age in an urban outpatient medical practice. Clin Endocrinol (Oxf) 2009; 70:788.</a></li><li><a class="nounderline abstract_t">Baloch Z, Carayon P, Conte-Devolx B, et al. Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease. Thyroid 2003; 13:3.</a></li><li><a class="nounderline abstract_t">Kratzsch J, Fiedler GM, Leichtle A, et al. New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid. Clin Chem 2005; 51:1480.</a></li><li><a class="nounderline abstract_t">Ekins R. The free hormone hypothesis and measurement of free hormones. Clin Chem 1992; 38:1289.</a></li><li><a class="nounderline abstract_t">Wong TK, Pekary AE, Hoo GS, et al. Comparison of methods for measuring free thyroxin in nonthyroidal illness. Clin Chem 1992; 38:720.</a></li><li><a class="nounderline abstract_t">Ross DS, Burch HB, Cooper DS, et al. 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid 2016; 26:1343.</a></li><li><a class="nounderline abstract_t">Larsen PR, Alexander NM, Chopra IJ, et al. Revised nomenclature for tests of thyroid hormones and thyroid-related proteins in serum. J Clin Endocrinol Metab 1987; 64:1089.</a></li><li><a class="nounderline abstract_t">Schmidt RL, LoPresti JS, McDermott MT, et al. Does Reverse Triiodothyronine Testing Have Clinical Utility? An Analysis of Practice Variation Based on Order Data from a National Reference Laboratory. Thyroid 2018; 28:842.</a></li><li><a class="nounderline abstract_t">de los Santos ET, Starich GH, Mazzaferri EL. Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients. Arch Intern Med 1989; 149:526.</a></li><li><a class="nounderline abstract_t">Schneider C, Feller M, Bauer DC, et al. Initial evaluation of thyroid dysfunction - Are simultaneous TSH and fT4 tests necessary? PLoS One 2018; 13:e0196631.</a></li><li><a class="nounderline abstract_t">DeGroot LJ, Mayor G. Admission screening by thyroid function tests in an acute general care teaching hospital. Am J Med 1992; 93:558.</a></li><li><a class="nounderline abstract_t">Ross DS. Screening thyroid function tests in an acute-care hospital. Am J Med 1994; 96:393.</a></li><li><a class="nounderline abstract_t">Franklyn JA, Black EG, Betteridge J, Sheppard MC. Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness. J Clin Endocrinol Metab 1994; 78:1368.</a></li><li><a class="nounderline abstract_t">Spencer C, Eigen A, Shen D, et al. Specificity of sensitive assays of thyrotropin (TSH) used to screen for thyroid disease in hospitalized patients. Clin Chem 1987; 33:1391.</a></li><li><a class="nounderline abstract_t">Carr D, McLeod DT, Parry G, Thornes HM. Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment. Clin Endocrinol (Oxf) 1988; 28:325.</a></li><li><a class="nounderline abstract_t">Jansen HI, Bult MM, Bisschop PH, et al. Increased fT4 concentrations in patients using levothyroxine without complete suppression of TSH. Endocr Connect 2023; 12.</a></li><li><a class="nounderline abstract_t">Barbesino G, Tomer Y. Clinical review: Clinical utility of TSH receptor antibodies. J Clin Endocrinol Metab 2013; 98:2247.</a></li><li><a class="nounderline abstract_t">Silva de Morais N, Angell TE, Ahmadi S, et al. Performance of Thyroid-Stimulating Immunoglobulin Bioassay and Thyrotropin-Binding Inhibitory Immunoglobulin Assay for the Diagnosis of Graves' Disease in Patients With Active Thyrotoxicosis. Endocr Pract 2022; 28:502.</a></li></ol></div><div id="topicVersionRevision">Topic 7891 Version 44.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2105333" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Applications of a new chemiluminometric thyrotropin assay to subnormal measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37655789" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Thyroid Stimulating Hormone and Thyroid Hormones (Triiodothyronine and Thyroxine): An American Thyroid Association-Commissioned Review of Current Clinical and Laboratory Status.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27043844" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Misdiagnosis of Graves' Disease with Apparent Severe Hyperthyroidism in a Patient Taking Biotin Megadoses.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28973622" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Association of Biotin Ingestion With Performance of Hormone and Nonhormone Assays in Healthy Adults.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28192572" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Biotin-Induced Biochemical Graves Disease: A Teachable Moment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2760176" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Measurement of thyrotropin in clinical and subclinical hyperthyroidism using a new chemiluminescent assay.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8565217" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Current status and performance goals for serum thyrotropin (TSH) assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2860333" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A new strategy for thyroid function testing.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2203796" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Clinical review 12: The use and misuse of the sensitive thyrotropin assays.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31664455" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : The Thyrotropin Reference Range Should Be Changed in Older Patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17911171" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Age-specific distribution of serum thyrotropin and antithyroid antibodies in the US population: implications for the prevalence of subclinical hypothyroidism.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22344200" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Age-related changes in thyroid function: a longitudinal study of a community-based cohort.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22879629" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Longitudinal changes in thyroid function in the oldest old and survival: the cardiovascular health study all-stars study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23345094" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Age- and gender-specific TSH reference intervals in people with no obvious thyroid disease in Tayside, Scotland: the Thyroid Epidemiology, Audit, and Research Study (TEARS).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36772798" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : The Impact of Age- and Sex-Specific Reference Ranges for Serum Thyrotropin and Free Thyroxine on the Diagnosis of Subclinical Thyroid Dysfunction: A Multicenter Study from Japan.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37696273" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : The optimal healthy ranges of thyroid function defined by the risk of cardiovascular disease and mortality: systematic review and individual participant data meta-analysis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/37407957" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : A systematic review of the relationship between normal range of serum thyroid-stimulating hormone and bone mineral density in the postmenopausal women.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/28276648" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Reference values for TSH may be inadequate to define hypothyroidism in persons with morbid obesity: <span class="__cf_email__" data-cfemail="4d09240d2f283963283e">[email protected]</span> study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18727705" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Reference limits of serum TSH and free T4 are significantly influenced by race and age in an urban outpatient medical practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12625976" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Laboratory medicine practice guidelines. Laboratory support for the diagnosis and monitoring of thyroid disease.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15961550" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : New reference intervals for thyrotropin and thyroid hormones based on National Academy of Clinical Biochemistry criteria and regular ultrasonography of the thyroid.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1307685" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : The free hormone hypothesis and measurement of free hormones.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1582025" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Comparison of methods for measuring free thyroxin in nonthyroidal illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27521067" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : 2016 American Thyroid Association Guidelines for Diagnosis and Management of Hyperthyroidism and Other Causes of Thyrotoxicosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3558727" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Revised nomenclature for tests of thyroid hormones and thyroid-related proteins in serum.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29756541" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Does Reverse Triiodothyronine Testing Have Clinical Utility? An Analysis of Practice Variation Based on Order Data from a National Reference Laboratory.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/2493228" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Sensitivity, specificity, and cost-effectiveness of the sensitive thyrotropin assay in the diagnosis of thyroid disease in ambulatory patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/29709030" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Initial evaluation of thyroid dysfunction - Are simultaneous TSH and fT4 tests necessary?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1442859" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Admission screening by thyroid function tests in an acute general care teaching hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8166164" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Screening thyroid function tests in an acute-care hospital.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8200938" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Comparison of second and third generation methods for measurement of serum thyrotropin in patients with overt hyperthyroidism, patients receiving thyroxine therapy, and those with nonthyroidal illness.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3301067" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Specificity of sensitive assays of thyrotropin (TSH) used to screen for thyroid disease in hospitalized patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3139338" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Fine adjustment of thyroxine replacement dosage: comparison of the thyrotrophin releasing hormone test using a sensitive thyrotrophin assay with measurement of free thyroid hormones and clinical assessment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/36762702" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Increased fT4 concentrations in patients using levothyroxine without complete suppression of TSH.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/23539719" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Clinical review: Clinical utility of TSH receptor antibodies.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/35091101" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Performance of Thyroid-Stimulating Immunoglobulin Bioassay and Thyrotropin-Binding Inhibitory Immunoglobulin Assay for the Diagnosis of Graves' Disease in Patients With Active Thyrotoxicosis.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
